Condition:   Psoriasis
Intervention:   Drug: etanercept 50 mg
Sponsors:   Innovaderm Research Inc.;   Amgen
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Cystic Fibrosis
Interventions:   Drug: azithromycin 250 mg tablets;   Drug: placebo tablets
Sponsors:   CF Therapeutics Development Network Coordinating Center;   Cystic Fibrosis Foundation
Completed - verified February 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate
Sponsors:   European Organization for Research and Treatment of Cancer;   Lymphoma Trials Office;   Groupe d'Etudes de Lymphomes de L'Adulte;   Grup per l'Estudi dels Limfomes de Catalunya i Balears;   NCIC Clinical Trials Group;   Australasian Leukaemia and Lymphoma Group (ALLG);   Nordic Lymphoma Group
Active, not recruiting - verified June 2009

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Procedure: adjuvant therapy;   Radiation: radiation therapy
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Radiation Therapy Oncology Group;   Southwest Oncology Group;   Trans-Tasman Radiation Oncology Group (TROG);   North Central Cancer Treatment Group
Active, not recruiting - verified March 2010